HR+, HER2-Negative Breast Cancer – Clinipace – OVELIA – Tolmar

Premenopausal women with HR+, HER2-Negative Breast Cancer and men with HR+ breast cancer are asked to participate in a research study being conducted by Montefiore Medical Center.

You may be eligible to participate in this study if you:

FEMALE:

  • Are age 18 to 55
  • Have a diagnosis of Stage I, II, or III HR+, HER2-negative breast cancer
  • Are premenopausal

MALE:

  • Are age 18 or older
  • Have a diagnosis of Stage I, II, or III HR+, HER2-negative breast cancer

You may NOT participate in this study if you:

FEMALE:

  • Are breastfeeding
  • Have unacceptable hepatic or renal function
  • Have a history of treatment for osteopenia/osteoporosis
  • Prior use of tamoxifen, other SERMs (eg, raloxifene) or antagonists (eg, fulvestrant), aromatase inhibitor, mTOR inhibitors, or hormone replacement therapy within 3 months before breast cancer diagnosis

MALE:

  • Have unacceptable hepatic or renal function
  • History of treatment for osteopenia/osteoporosis
  • Prior use of tamoxifen, other SERMs (eg, raloxifene) or antagonists (eg, fulvestrant), aromatase inhibitor, mTOR inhibitors, or hormone replacement therapy within 3 months before breast cancer diagnosis

Please refer to our ClinicalTrials.gov – CLICK HERE – for extensive information about the Tolmar Clinical Trial.
Contact Information

Ambar Baez, Study Coordinator

1695 Eastchester Road Bronx, NY 10461
Phone: (718) 405-8578
Fax: (718) 405-8230
Email: ambaez@montefiore.org